Amyris Inc Innovations and Intellectual Property

Amyris Inc has developed a robust intellectual property portfolio, with over 500 patents and patent applications worldwide. This portfolio is a testament to the company's innovative approach to biotechnology.

Amyris has patented its proprietary yeast strain, which is the backbone of its production process, allowing for the efficient conversion of sugars into valuable chemicals and biofuels. This patented technology has been licensed to various partners around the world.

The company's innovative approach has led to the development of a wide range of products, including renewable fuels, chemicals, and pharmaceuticals.

Broaden your view: The Duckhorn Portfolio

Amyris, Inc. is a biotechnology company that has been publicly traded since 2009. It's listed on the NASDAQ stock exchange under the ticker symbol AMRS.

Amyris has received funding from various investors, including the Bill and Melinda Gates Foundation.

The company has a market capitalization of over $1 billion, giving it a significant presence in the biotech industry.

Amyris, Inc. has been making waves in the industry with some significant updates. In September 2023, Amyris, Inc. appointed Dr. Sunil Chandran as their new Chief Technology Officer.

Amyris, Inc. has also been expanding its operations, as seen in May 2023 when they acquired the remaining 31% stake in their Industrial Precision Fermentation Plant in Barra Bonita, Brazil from Ingredion Incorporated.

In a major development, Amyris, Inc. emerged from bankruptcy in May 2023. This move marked a significant turning point for the company and paved the way for future growth.

Here's a quick rundown of the key updates:

Amyris, Inc. has also made some changes to its leadership team, with Han Kieftenbeld leaving as Chief Financial Officer in May 2023. Kathy L. Fortmann joined the company as a member of the Board of Directors around the same time.

Amyris, Inc. has been the subject of various analyst recommendations over the past year.

In May 2018, Jefferies downgraded Amyris to Hold from Buy, adjusting the price target to $0.65 from $3.10.

Canaccord Genuity initiated coverage of Amyris with a Buy rating and a price target of $1.50 in April 2018.

Piper Sandler adjusted Amyris' price target to $1 from $1.50 in April 2018, while maintaining a Neutral rating.

On the other hand, JPMorgan downgraded Amyris to Underweight from Neutral in November 2022.

Oppenheimer also downgraded Amyris to Perform from Outperform in November 2022, removing the $22 price target.

Here's a summary of the analyst recommendations:

At Amyris, Inc., the leadership team is made up of experienced professionals who have been with the company for various lengths of time. Kathy Fortmann is the CEO and has been in the role since May 6, 2024.

Kathy Fortmann is 58 years old and has been with the company for a relatively short period. Sunil Chandran, on the other hand, has been with Amyris since December 31, 2005, making him a long-time member of the team.

Sunil Chandran's exact age is not listed, but Philip Gund, another corporate officer, is 63 years old. Philip has been with the company since August 8, 2023.

Additional reading: Paramount Communications, Inc. V. Time Inc.

The board of directors at Amyris includes John Doerr, Ryan Panchadsaram, and J. White. John Doerr is 73 years old and has been a director since April 30, 2006. Ryan Panchadsaram is 40 years old and has been a director since August 9, 2021. J. White is 57 years old and has been a director since August 28, 2023.

Here is a list of the current managers and directors at Amyris, Inc.:

The United States Bankruptcy Court retained The Michel-Shaked Group as Expert Consultant for Amyris, Inc. and its affiliated debtors.

The Michel-Shaked Group conducted an enterprise valuation of Amyris on a going concern basis, as well as a valuation of Amyris’ intellectual property assets.

Bradley M. Orelowitz used an approach based on the brand to enterprise value ratio, also known as the brand profit split, reported in MARKABLES.

This approach involves reviewing and analyzing purchase prices paid by third-parties to buy each consumer brand business, then determining the proportion of the purchase price attributable to the brand IP.

The MARKABLES database was used to identify comparable transactions for this analysis.

The brand profit split method is often used as a hygiene check for the RFR method, but in this case, it was used as a stand-alone method.

The reliability of the IP to enterprise value ratio as retrievable from purchase price allocations was demonstrated in this approach.

This method is worth considering for any IP valuation.

Amyris, Inc. has successfully executed several business transactions that have contributed to its growth and success.

The company partnered with Novozymes to develop a yeast-based fermentation process for the production of farnesene, a sustainable alternative to petroleum-based chemicals.

Amyris has also formed partnerships with major companies such as Unilever and Procter & Gamble to commercialize its products.

These partnerships have enabled Amyris to scale up its production and expand its market reach.

Business transactions can be complex and time-consuming, but staying on top of the latest filings can help you navigate the process with ease.

The latest SEC filings for a specific company reveal a flurry of activity in May 2024.

On May 7, 2024, the company filed a SC 13D/A form, which is an amendment to a general statement of acquisition of beneficial ownership.

In addition to the SC 13D/A form, the company also filed a 15-12G form on May 7, 2024, which is a securities registration termination.

The same day, the company filed an 8-K form, which is a current report.

The company's 8-K filings on April 23, 2024, and April 8, 2024, indicate that the company is actively reporting its current status.

On April 2, 2024, the company filed an NT 10-K form, which is a notification of inability to timely file Form 10-K.

In February 2024, the company filed multiple EFFECT forms, which are notices of effectiveness.

Here is a summary of the company's latest SEC filings:

Amyris has made a significant move by auctioning off four consumer brands from its portfolio, including Biossance, a "clean" skin care label.

The biotech beauty company filed for voluntary Chapter 11 bankruptcy in August, which led to the auction of its consumer brands.

The US business of THG Beauty successfully bid $20m for Biossance, whose products are based on a hydrating molecule made from sustainable fermented sugarcane.

Amyris stated it would exit all of its consumer brands but continue to operate them through retail partners and e-commerce platforms during the sale process.

A fresh viewpoint: Marquee Brands